Carrie Richardson, MD
Rheumatology · Chicago, ILNPI 1477817021
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $412 of the $593 with a category attached, or 69.5%. Novartis accounts for 66.2% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for rheumatology clinicians in IL, where the typical reported total is $1,267.
Across 5 payments — averaging $118.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$393
- Boehringer Ingelheim$118
- Amgen$82
Across 13 payments — averaging $1641.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$15K
- Boehringer Ingelheim International GmbH$7K
What the payments were for
- Travel & lodging$18131%
- Food & beverage$41269%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $393 |
| Boehringer Ingelheim | 1 | $118 |
| Amgen | 1 | $82 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$118
How this compares
$593 in reported general payments places this provider in the 35th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 79 | $368,444 |
| Humira(Cf) PenAdalimumab | 29 | $277,374 |
| XeljanzTofacitinib Citrate | 33 | $227,781 |
| Cosentyx Sensoready PenSecukinumab | 11 | $192,521 |
| Humira(Cf)Adalimumab | 13 | $159,037 |
| Orencia ClickjectAbatacept | 18 | $128,958 |
| ActemraTocilizumab | 25 | $112,921 |
| Mycophenolic AcidMycophenolate Sodium | 26 | $22,250 |
| Mycophenolate Mofetil | 108 | $22,093 |
| Sildenafil Citrate | 77 | $11,897 |
| Esomeprazole Magnesium | 11 | $3,638 |
| Hydroxychloroquine Sulfate | 89 | $2,764 |
| Leflunomide | 22 | $2,705 |
| Colchicine | 24 | $2,026 |
| Pilocarpine Hcl | 20 | $1,980 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Chicago
- Manish JainChicago$1.9M
- Theodore PincusChicago$524K
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Robert WoodrickChicago$143K
- Maria SosenkoChicago$87K
- Ailda NikaChicago$74K
- Duncan MooreChicago$71K
- Timothy NiewoldChicago$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.